Evidence map›Paper›PMID 30715675›Full record

ArticlePathology oncology research : POR2020

BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.

Chiraz Mehemmai, Farid Cherbal, Yosr Hamdi, Abdelmoumene Guedioura, Wassila Benbrahim, Rabah Bakour, Sonia Abdelhak

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Prevalence of Clinically Relevant GermlineFrontiers in genetics · 2022
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Chiraz MehemmaiUnit of Genetics, Laboratory of Molecular and Cellular Biology, Faculty of Biological Sciences, USTHB, POB 32 El Alia, Bab Ezzouar, 16111, Algiers, Algeria.
Farid CherbalUnit of Genetics, Laboratory of Molecular and Cellular Biology, Faculty of Biological Sciences, USTHB, POB 32 El Alia, Bab Ezzouar, 16111, Algiers, Algeria. farid.cherbal@gmail.com.ORCID http://orcid.org/0000-0001-7338-1252
Yosr HamdiLaboratory of Biomedical Genomics and Oncogenetics (LRTI, IPT 05), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.
Abdelmoumene GuediouraLOBEM, Faculty of Biological Sciences, USTHB, Algiers, Algeria.
Wassila BenbrahimAnti-cancer center of Batna, Batna, Algeria.
Rabah BakourUnit of Genetics, Laboratory of Molecular and Cellular Biology, Faculty of Biological Sciences, USTHB, POB 32 El Alia, Bab Ezzouar, 16111, Algiers, Algeria.
Sonia AbdelhakLaboratory of Biomedical Genomics and Oncogenetics (LRTI, IPT 05), Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.
Tunis University · TNUniversity of Sciences and Technology Houari Boumediene · DZUniversity of Batna 1 · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is currently the leading cause of cancer morbidity and mortality among Algerian women. In this study, we aimed to investigate the mutation spectrum of BRCA1 and BRCA2 genes in hereditary breast/ovarian cancer (HBOC) families from the Aures region (eastern Algeria). High risk breast/ovarian cancer families were selected from overall 1162 consecutive patients collected from cancer registry of anticancer center of Batna. Breast cancers were diagnosed between 2011 and 2015. Recurrent mutations on BRCA1 and BRCA2 previously found in Algerian patients were screened using PCR-direct sequencing in 113 HBOC families. In addition, for the first time in Algeria, HBOC patients were analyzed by NGS using a cancer panel of 30 hereditary cancer genes or BRCA1/2 genetic test. Six distinct deleterious mutations in BRCA1 and BRCA2 and a new VUS in PALB2 were detected in ten patients. Two distinct BRCA2 pathogenic variants c.1813dupA and c.8485C > T detected in two young female triple negative breast cancer (TNBC) patients, respectively, with a family history of male breast cancer, are reported here for the first time in Algerian population. Interestingly, we also detected a BRCA exon 15 deletion in two unrelated young female TNBC patients with strong family history of breast/ovarian cancer. Our study showed differences in the distribution of the mutation spectrum of BRCA genes between the Aures region and the north central region of Algeria. Our results will contribute in the implementation of genetic counseling and testing for patients and families at risk of hereditary breast and ovarian cancer.

Indexed as

AdultAgedAlgeriaBRCA1 ProteinBRCA2 ProteinDNA Mutational AnalysisFemaleGerm-Line MutationHereditary Breast and Ovarian Cancer SyndromeHumansMiddle AgedBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanAlgerian womenAures regionBRCA1BRCA2Cancer panelGenetic testingHBOCNGS

Identifiers

PMID30715675
OpenAlexW4232884262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.